Drug intelligence / Profile preview

mogrol

Development stage
Preclinical
Modality
Small Molecules
Administration
Oral
01

Overview

**Mogrol** is a naturally occurring tetracyclic triterpenoid and the aglycone (non-sugar part) of mogrosides, primarily derived from *Siraitia grosvenorii* (monk fruit), widely used in traditional Chinese medicine and as a natural sweetener source[1][3][5]. Mogrol is formed in the body from mogrosides after oral ingestion by deglycosylation through gastrointestinal enzymes and microbiota[1][3].\nMogrol exhibits multiple pharmacological effects, including:\n- **Activation of AMP-activated protein kinase (AMPK)**, leading to anti-obesity, anti-inflammatory, and anti-diabetes activity\n- **Inhibition of ERK1/2 and STAT3 pathways** (anticancer effect, including inhibition of leukemia and lung cancer cell proliferation)\n- **Inhibition of CREB activation** (reducing adipogenesis)\n- **Neuroprotective effects** (inhibition of NF-κB pathway)\n- **Suppression of osteoclast formation and bone resorption** (potential anti-osteoporosis effect through inhibition of TRAF6 recruitment and MAPK/NF-κB signaling)\n- Potential alleviation of inflammatory conditions (e.g., ulcerative colitis) via inhibition of inflammatory mediator production[3][5][11].

Other names
3α-hydroxymogrol(3S,8S,9R,10R,11R,13R,14S,17R)-17-[(2R,5R)-5,6-dihydroxy-6-methylheptan-2-yl]-4,4,9,13,14-pentamethyl-2,3,7,8,10,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthrene-3,11-diol(10α,24R)-9β-methyl-19-norlanosta-5-ene-3β,11α,24,25-tetrol
02

Targets

AMPK (Adenosine monophosphate–activated protein kinase)GPBAR1 (G protein-coupled bile acid receptor 1)STAT3 (Signal Transducer and Activator of Transcription 3)MAPK3 (Mitogen-activated protein kinase 1)CREB (Cyclic AMP response element-binding protein)

Beyond the preview

Go deeper on mogrol.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on mogrol.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call